Celleo Biotech is making use of Integra Biosciences’ Pipetboy Genius serological pipet controller to streamline the development and manufacturing of novel cell and gene therapies.

Many genetic diseases involve multiple mutations, making them hard to treat. A new retron-based gene-editing method from UT Austin offers hope by repairing entire defective DNA regions — paving the way for more inclusive, affordable, and wide-reaching gene therapies.

Designed for full climate-neutral operations, the new filter manufacturing facility is a landmark project for Merck as its in line with the company’s aim to achieve climate neutrality by 2040.

A new gene therapy developed at UC San Diego may offer a breakthrough in Alzheimer’s treatment by reprogramming brain cells to preserve memory and cognitive function — potentially tackling the disease at its source rather than managing symptoms.

Researchers at Kaist have developed the first technology to selectively acetylate specific RNA molecules inside living cells using the CRISPR-Cas13 system. This breakthrough enables precise, programmable control of RNA function and marks a major step forward in RNA-based therapeutics and gene regulation research.

Researchers have recently tested a Crispr/Cas9 gene-editing technique to help the immune system in a person’s body to fight advanced gastrointestinal cancers. The results have revealed promising signs of safety and potential effectiveness of the treatment.

Thermo Fisher Scientific announced the expansion of its central laboratory operations in Kentucky, USA. With this move, the company’s PPD clinical research business will almost double its laboratory footprint in the region.

The platform called Nanostraw Electro-actuated Transfection (Next) uses tiny hollow nanostructures and electrical pulses to insert a wide variety of biomolecules — proteins, mRNA and gene-editing tools — into immune cells with high efficiency and minimal disruption.

Scientists from Arc Institute and NVIDIA have developed a new AI model – Evo 2. The model is capable of identifying patterns in gene sequences across disparate organisms that experimental researchers would need years to uncover.

Researchers at the University of Cambridge have identified the genetic mutation causing progressive retinal atrophy (PRA) in English Shepherd Dogs and developed a DNA test for it. This allows breeders to identify carriers and avoid passing the disease to puppies, potentially eliminating PRA from the breed. The test costs £48.